Trevi Therapeutics Announces Clinical Trial Progress and Extended Cash Runway Through 2030
Trevi Therapeutics (TRVI) has provided updates regarding its clinical pipeline, confirming the initiation of both the OCEAN-1 and OCEAN-2 trials. The company has successfully secured regulatory approval from all relevant authorities in every country where it is currently conducting clinical studies. Looking ahead, Trevi outlines plans to begin a non-IPF-ILD Phase II trial in the first quarter of 2027. Crucially for investors, management indicated that the company's current cash runway has been extended into 2030, providing significant long-term operational stability as they advance their clinical programs.
Tickers: $TRVI